Molecular Partners AG (6ML) Q4 2024 Earnings Report

Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.

During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.